Decreased levels of d-aspartate and NMDA in the prefrontal cortex and striatum of patients with schizophrenia

Journal of Psychiatric Research

Volumn 47, Issue 10, 2013, Pages 1432-1437

  Errico, Francesco ^a,b   Napolitano, Francesco ^a   Squillace, Marta ^a   Vitucci, Daniela ^a,c   Blasi, Giuseppe ^d   de Bartolomeis, Andrea ^e   Bertolino, Alessandro ^d   D'Aniello, Antimo ^f   Usiello, Alessandro ^a,g  

^a CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

^d UNIVERSITY OF BARI   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f STAZIONE ZOOLOGICA ANTON DOHRN   (Italy)

^g SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

D Aspartate; D Serine; NMDA receptors; Schizophrenia

Indexed keywords

DEXTRO AMINO ACID; DEXTRO ASPARTIC ACID; GLUTAMATE RECEPTOR; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; HUMAN; HUMAN TISSUE; NEUROTRANSMISSION; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; SCHIZOPHRENIA;

D-ASPARTATE; D-SERINE; NMDA RECEPTORS; SCHIZOPHRENIA;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ASPARTIC ACID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; FEMALE; HUMANS; MALE; MIDDLE AGED; N-METHYLASPARTATE; POSTMORTEM CHANGES; PREFRONTAL CORTEX; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 84881557265     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.06.013     Document Type: Article

References (59)

1. Bendikov I., Nadri C., Amar S., Panizzutti R., De Miranda J., Wolosker H., et al. ACSF and postmortem brain study of d-serine metabolic parameters in schizophrenia. Schizophrenia Research 2007, 90:41-51.
2. Billard J.M. d-Amino acids in brain neurotransmission and synaptic plasticity. Amino Acids 2012, 43:1851-1860.
3. Coyle J.T. NMDA receptor and schizophrenia: a brief history. Schizophrenia Bulletin 2012, 38:920-926.
4. Coyle J.T., Tsai G., Goff D.C. Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Current Drug Targets - CNS & Neurological Disorders 2002, 1:183-189.
5. D'Aniello A., Di Fiore M.M., Fisher G.H., Milone A., Seleni A., et al. Occurrence of d-aspartic acid and N-methyl-d-aspartic acid in rat neuroendocrine tissues and their role in the modulation of luteinizing hormone and growth hormone release. FASEB Journal 2000, 14:699-714.
6. D'Aniello G., Tolino A., D'Aniello A., Errico F., Fisher G.H., Di Fiore M.M. The role of d-aspartic acid and N-methyl-d-aspartic acid in the regulation of prolactin release. Endocrinology 2000, 141:3862-3870.
7. D'Aniello S., Somorjai I., Garcia-Fernandez J., Topo E., D'Aniello A. d-Aspartic acid is a novel endogenous neurotransmitter. FASEB Journal 2011, 25:1014-1027.
8. D'Aniello S., Spinelli P., Ferrandino G., Peterson K., Tsesarskia M., Fisher G., et al. Cephalopod vision involves dicarboxylic amino acids: d-aspartate, l-aspartate and l-glutamate. Biochemical Journal 2005, 386:331-340.
9. de Bartolomeis A., Sarappa C., Magara S., Iasevoli F. Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia. European Journal of Pharmacology 2012, 682:1-11.
10. Dracheva S., Marras S.A., Elhakem S.L., Kramer F.R., Davis K.L., Haroutunian V. N-methyl-d-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. American Journal of Psychiatry 2001, 158:1400-1410.
11. Errico F., Napolitano F., Nistico R., Usiello A. New insights on the role of free d-aspartate in the mammalian brain. Amino Acids 2012, 43:1861-1871.
12. Errico F., Nistico R., Napolitano F., Mazzola C., Astone D., Pisapia T., et al. Increased d-aspartate brain content rescues hippocampal age-related synaptic plasticity deterioration of mice. Neurobiology of Aging 2011, 32:2229-2243.
13. Errico F., Nistico R., Napolitano F., Oliva A.B., Romano R., Barbieri F., et al. Persistent increase of d-aspartate in d-aspartate oxidase mutant mice induces a precocious hippocampal age-dependent synaptic plasticity and spatial memory decay. Neurobiology of Aging 2011, 32:2061-2074.
14. Errico F., Nistico R., Palma G., Federici M., Affuso A., Brilli E., et al. Increased levels of d-aspartate in the hippocampus enhance LTP but do not facilitate cognitive flexibility. Molecular and Cellular Neuroscience 2008, 37:236-246.
15. Errico F., Pirro M.T., Affuso A., Spinelli P., De Felice M., D'Aniello A., et al. Aphysiological mechanism to regulate d-aspartic acid and NMDA levels in mammals revealed by d-aspartate oxidase deficient mice. Gene 2006, 374:50-57.
16. Errico F., Rossi S., Napolitano F., Catuogno V., Topo E., Fisone G., et al. d-Aspartate prevents corticostriatal long-term depression and attenuates schizophrenia-like symptoms induced by amphetamine and MK-801. Journal of Neuroscience 2008, 28:10404-10414.
17. Fagg G.E., Matus A. Selective association of N-methyl aspartate and quisqualate types of l-glutamate receptor with brain postsynaptic densities. Proceedings of the National Academy of Sciences of the United States of America 1984, 81:6876-6880.
18. Fuchs S.A., Berger R., Klomp L.W., de Koning T.J. d-Amino acids in the central nervous system in health and disease. Molecular Genetics and Metabolism 2005, 85:168-180.
19. Goff D.C., Tsai G., Manoach D.S., Coyle J.T. Dose-finding trial of d-cycloserine added to neuroleptics for negative symptoms in schizophrenia. American Journal of Psychiatry 1995, 152:1213-1215.
20. Hashimoto A., Kumashiro S., Nishikawa T., Oka T., Takahashi K., Mito T., et al. Embryonic development and postnatal changes in free d-aspartate and d-serine in the human prefrontal cortex. Journal of Neurochemistry 1993, 61:348-351.
21. Hashimoto A., Oka T. Free d-aspartate and d-serine in the mammalian brain and periphery. Progress in Neurobiology 1997, 52:325-353.
22. Hashimoto A., Oka T., Nishikawa T. Anatomical distribution and postnatal changes in endogenous free d-aspartate and d-serine in rat brain and periphery. European Journal of Neuroscience 1995, 7:1657-1663.
23. Hashimoto K., Engberg G., Shimizu E., Nordin C., Lindstrom L.H., Iyo M. Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2005, 29:767-769.
24. Hashimoto K., Fukushima T., Shimizu E., Komatsu N., Watanabe H., Shinoda N., et al. Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia. Archives of General Psychiatry 2003, 60:572-576.
25. Hashimoto K., Sawa A., Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biological Psychiatry 2007, 62:1310-1316.
26. Heresco-Levy U., Ermilov M., Shimoni J., Shapira B., Silipo G., Javitt D.C. Placebo-controlled trial of d-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. American Journal of Psychiatry 2002, 159:480-482.
27. Heresco-Levy U., Javitt D.C., Ebstein R., Vass A., Lichtenberg P., Bar G., et al. d-Serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biological Psychiatry 2005, 57:577-585.
28. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophrenia Bulletin 2009, 35:549-562.
29. Huang A.S., Beigneux A., Weil Z.M., Kim P.M., Molliver M.E., Blackshaw S., et al. d-Aspartate regulates melanocortin formation and function: behavioral alterations in d-aspartate oxidase-deficient mice. Journal of Neuroscience 2006, 26:2814-2819.
30. Ikonomidou C., Bittigau P., Koch C., Genz K., Hoerster F., Felderhoff-Mueser U., et al. Neurotransmitters and apoptosis in the developing brain. Biochemical Pharmacology 2001, 62:401-405.
31. Javitt D.C. Twenty-five years of glutamate in schizophrenia: are we there yet?. Schizophrenia Bulletin 2012, 38:911-913.
32. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U., Lindenmayer J.P. Amelioration of negative symptoms in schizophrenia by glycine. American Journal of Psychiatry 1994, 151:1234-1236.
33. Kim P.M., Duan X., Huang A.S., Liu C.Y., Ming G.L., Song H., et al. Aspartate racemase, generating neuronal d-aspartate, regulates adult neurogenesis. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:3175-3179.
34. Krebs H.A. Metabolism of amino-acids: deamination of amino-acids. Biochemical Journal 1935, 29:1620-1644.
35. Kristiansen L.V., Beneyto M., Haroutunian V., Meador-Woodruff J.H. Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia. Molecular Psychiatry 2006, 11:737-747. 705.
36. Kristiansen L.V., Huerta I., Beneyto M., Meador-Woodruff J.H. NMDA receptors and schizophrenia. Current Opinion in Pharmacology 2007, 7:48-55.
37. Labrie V., Wong A.H., Roder J.C. Contributions of the d-serine pathway to schizophrenia. Neuropharmacology 2012, 62:1484-1503.
38. Martineau M., Baux G., Mothet J.P. d-Serine signalling in the brain: friend and foe. Trends in Neurosciences 2006, 29:481-491.
39. Meador-Woodruff J.H., Healy D.J. Glutamate receptor expression in schizophrenic brain. Brain Research. Brain Research Reviews 2000, 31:288-294.
40. Meador-Woodruff J.H., Hogg A.J., Smith R.E. Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder. Brain Research Bulletin 2001, 55:631-640.
41. Mohler H., Boison D., Singer P., Feldon J., Pauly-Evers M., Yee B.K. Glycine transporter 1 as a potential therapeutic target for schizophrenia-related symptoms: evidence from genetically modified mouse models and pharmacological inhibition. Biochemical Pharmacology 2011, 81:1065-1077.
42. Nacher J., McEwen B.S. The role of N-methyl-d-aspartate receptors in neurogenesis. Hippocampus 2006, 16:267-270.
43. Ohtsuki T., Sakurai K., Dou H., Toru M., Yamakawa-Kobayashi K., Arinami T. Mutation analysis of the NMDAR2B (GRIN2B) gene in schizophrenia. Molecular Psychiatry 2001, 6:211-216.
44. Ota N., Shi T., Sweedler J.V. d-Aspartate acts as a signaling molecule in nervous and neuroendocrine systems. Amino Acids 2012, 43:1873-1886.
45. Papouin T., Ladepeche L., Ruel J., Sacchi S., Labasque M., Hanini M., et al. Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 2012, 150:633-646.
46. Ritter L.M., Vazquez D.M., Meador-Woodruff J.H. Ontogeny of ionotropic glutamate receptor subunit expression in the rat hippocampus. Brain Research. Developmental Brain Research 2002, 139:227-236.
47. Sacchi S., Caldinelli L., Cappelletti P., Pollegioni L., Molla G. Structure-function relationships in human d-amino acid oxidase. Amino Acids 2012, 43:1833-1850.
48. Sakai K., Homma H., Lee J.A., Fukushima T., Santa T., Tashiro K., et al. Emergence of d-aspartic acid in the differentiating neurons of the rat central nervous system. Brain Research 1998, 808:65-71.
49. Sawa A., Snyder S.H. Schizophrenia: neural mechanisms for novel therapies. Molecular Medicine 2003, 9:3-9.
50. Sokolov B.P. Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of neuroleptic-free schizophrenics: evidence on reversible up-regulation by typical neuroleptics. Journal of Neurochemistry 1998, 71:2454-2464.
51. Tan H.Y., Callicott J.H., Weinberger D.R. Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. Cerebral Cortex 2007, 17(Suppl.1):i171-i181.
52. Tang J., Chen X., Xu X., Wu R., Zhao J., Hu Z., et al. Significant linkage and association between a functional (GT)n polymorphism in promoter of the N-methyl-d-aspartate receptor subunit gene (GRIN2A) and schizophrenia. Neuroscience Letters 2006, 409:80-82.
53. Tsai G., Yang P., Chung L.C., Lange N., Coyle J.T. d-Serine added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry 1998, 44:1081-1089.
54. Tsai G.E., Yang P., Chung L.C., Tsai I.C., Tsai C.W., Coyle J.T. d-Serine added to clozapine for the treatment of schizophrenia. American Journal of Psychiatry 1999, 156:1822-1825.
55. Vrajova M., Stastny F., Horacek J., Lochman J., Sery O., Pekova S., et al. Expression of the hippocampal NMDA receptor GluN1 subunit and its splicing isoforms in schizophrenia: postmortem study. Neurochemical Research 2010, 35:994-1002.
56. Weickert C.S., Fung S.J., Catts V.S., Schofield P.R., Allen K.M., Moore L.T., et al. Molecular evidence of N-methyl-d-aspartate receptor hypofunction in schizophrenia. Molecular Psychiatry 2012.
57. Wolosker H., D'Aniello A., Snyder S.H. d-Aspartate disposition in neuronal and endocrine tissues: ontogeny, biosynthesis and release. Neuroscience 2000, 100:183-189.
58. Yamanaka M., Miyoshi Y., Ohide H., Hamase K., Konno R. d-Amino acids in the brain and mutant rodents lacking d-amino-acid oxidase activity. Amino Acids 2012, 43:1811-1821.
59. Zhao X., Li H., Shi Y., Tang R., Chen W., Liu J., et al. Significant association between the genetic variations in the 5' end of the N-methyl-d-aspartate receptor subunit gene GRIN1 and schizophrenia. Biological Psychiatry 2006, 59:747-753.